Shire is prepping a plan to cut back on its sizable research operations in Basingstoke, U.K.--another setback for the country's research industry with Novartis axing more than 500 staffers and consultants in Horsham following major blows from AstraZeneca and Pfizer.
The Boston Globe reports this morning that Novartis told staffers on Wednesday that it will shutter a cancer research program in Emeryville, CA, as it cuts about 500 research staffers from the payroll and adds 175 to its booming operations in the Boston-area biotech hub.
With Sanofi having already begun enrollment for its 15,000-person Phase III trial, the French company has a clear lead in the race to develop a Clostridium difficile vaccine, but a growing pack is in pursuit. The latest to give chase is a group of European scientists with a new angle--they are developing an oral vaccine.
RNA delivery specialist Arrowead Research heralded new data supporting its genetic treatment for hepatitis B, which makes use of the company's polymer-based method for effectively getting RNAi to the nucleus. And its immunological response offers what could be a "functional cure" for the disease.
If you want to cripple cancer cells, go straight for their power source, according to researchers at MIT and the University of Toronto. The scientists have developed a delivery method for the cancer drug cisplatin that sends it straight to the energy-producing mitochondria of the offending cells.
GlaxoSmithKline has rounded up some early preclinical projects in its inaugural Discovery Fast Track competition, hand-picking academic scientists for a chance to partner up and kick-start their research into a development program.
Novartis is bringing the ax down on close to 400 R&D jobs at its respiratory R&D center in West Sussex in the U.K., signaling that the restructuring is part of a broader global realignment.
After ditching a planned private raise, Utah's Lipocine is looking to the boiling public market for biotechs, filing an S-1 for $11.5 million to fund its oral testosterone replacement therapy.
With healthcare officials around the world ringing alarm bells over a weak global pipeline of antibiotics, Roche's pRED group is making good on its promised return to the field with a $560 million development deal, partnering up with a Phase II program underway at Polyphor.
2012 Fierce 15 member Celladon has boosted its IPO goals, seeking as much as $92 million to help get its gene therapy for heart failure through a Phase IIb study and into Phase III.